Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
Executive Summary
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
You may also be interested in...
Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic
Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.